Insertion of CD16-158V augmented the ADCC function of CD38KO NK cells against B-cell and myeloma tumor targets and elicited superior CD38-directed antitumor activity in vivo in a myeloma mouse model, underscoring the potential of this approach to generate modified NK cells that optimize CD38-directed immunotherapy. Here, FCGR3A is linked to plasma cell myeloma.